Body Composition Stack
GH secretagogues + fat oxidation for body recomposition research.
Extends the CJC/Ipamorelin base with AOD-9604 for targeted lipolysis and MOTS-c for mitochondrial biogenesis. This stack covers GH secretion, fat oxidation, and mitochondrial efficiency simultaneously.
What's in this stack
Research Protocol
- CJC-1295 + Ipamorelin: 100+100 mcg pre-sleep
- AOD-9604: 300 mcg AM fasted
- MOTS-c: 5 mg twice weekly
Ready to start your Body Composition Stack research?
Each compound ships COA-verified, >98% purity, cold-packed for stability.
Frequently Asked Questions
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist that also targets the glucagon receptor, producing additive effects on energy expenditure beyond GLP-1 alone. Phase 2 data showed up to 24% body weight reduction for Retatrutide vs ~20% for Tirzepatide.
How do GH secretagogues like CJC-1295 and Ipamorelin work?
CJC-1295 is a GHRH analogue that stimulates pituitary GH release with an extended half-life due to DAC modification. Ipamorelin is a selective GHRP that triggers GH pulse without cortisol or prolactin elevation. Combined, they produce synergistic GH secretion through complementary receptor pathways.
Are GLP-1 peptide agonists available in oral format?
Orforglipron is a non-peptide GLP-1 receptor agonist with documented oral bioavailability, it is structurally resistant to peptidase degradation. Retatrutide and Tirzepatide are also available as capsules at Rainbow Peptide for oral administration research.
What does PT-141 research focus on?
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for its role in sexual function and arousal pathways. It acts centrally via MC3R and MC4R, differentiating it from vascular-acting compounds like PDE5 inhibitors.
For research use only. Not intended for human consumption. Must be 18+.